Replies to post #158521 on Biotech Values

[DewDiligence]

More info on Kathleen Uhl (acting head of OGD):

http://in.reuters.com/article/2013/03/19/us-fda-generics-director-idINBRE92I15H20130319

Uhl, who obtained a medical degree from the Medical College of Pennsylvania, joined the FDA in 1998 in a clinical pharmacology division. She spent five years as assistant commissioner for women's health and as director of FDA's Office of Women's Health.

In 2010, Uhl became deputy director in the office of medical policy. Woodcock said in her memo to staff that Uhl provided "exemplary leadership" of that office as it underwent a major organizational change by becoming a "Super office," or one that houses subordinate offices. Part of the current realignment of the generic drugs office involves it too becoming a "Super Office."